Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 100 Campus Drive FLORHAM PARK NJ 07932 |
Tel: | 1-212-9153820 |
Website: | https://www.cellectar.com |
IR: | See website |
Key People | ||
James V. Caruso President, Chief Executive Officer, Director | Chad J. Kolean Chief Financial Officer, Vice President, Secretary | Jarrod Longcor Chief Operating Officer |
Andrei Shustov Senior Vice President - Medical | Shane Lea Chief Commercial Officer |
Business Overview |
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. Its Iopofosine is evaluated in the completed CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstrom's macroglobulinemia (WM). |
Financial Overview |
For the fiscal year ended 31 December 2023, Cellectar Biosciences Inc revenues was not reported. Net loss increased 33% to $38M. Higher net loss reflects Reaserch and development increase of 45% to $27.7M (expense), General and administrative increase of 48% to $1.9M (expense), General and administrative increase of 6% to $8.8M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$4.05 to -$3.11. |
Employees: | 20 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $99.41M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$38.77M as of Dec 31, 2023 |
Net annual income (TTM): | -$37.98M as of Dec 31, 2023 |
Free cash flow (TTM): | -$33.24M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 32,260,510 as of Dec 31, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |